Neuroprotective Strategies of Blood-Brain Barrier Penetrant “Forskolin” (AC/cAMP/PKA/CREB Activator) to Ameliorate Mitochondrial Dysfunctioning in Neurotoxic Experimental Model of Autism

New developments in the study of brain are among the most exciting frontiers of contemporary neuroscientific research for the clinical practitioner. Increasing knowledge of neurocomplications and of their discrete localization in the various regions of brain permits new modes of pharmacological management of some major neurological disorders like autism. The research work reported in this scheme is undertaken with an objective to explore the potential molecular targets (AC/cAMP/PKA/CREB) for the development of newer therapeutics strategies (forskolin) for the management of neurological disorders and associated symptoms. Studies aimed at addressing these questions have fallen into two main categories: in-vivo behavioral paradigms and in-vitro differentiation biochemical, morphological and histopathological analysis. Therefore, first time, we aim to gather the propensity of mitochondrial cofactors, neuropathological mechanisms and various diagnostic methods to explore the clinical therapeutic strategies to ameliorate the neurodevelopmental disorder autism.